FDA Accepts Eisai's sNDA Application for Aricept In the Treatment of Severe Alzheimer's Disease
Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO Haruo Naito) announced today that the FDA (U.S. Food and Drug Administration) has accepted a supplemental New Drug Application (sNDA) for Aricept (donepezil HCl tablet) for the treatment of severe Alzheimer's Disease on February 13, 2006. Eisai Medical Research Inc. (Headquarters: New Jersey, President: Mindell Seidlin), a U.S. subsidiary of Eisai Co., Ltd. submitted the revised application on December 16, 2005.
Corporate Communications Department
Eisai Co., Ltd.